Taketoshi Nara

Inhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice

Mingguo Huang, Shintaro Narita, Hiromi Sato, Yuya Sekine et autres

Fatty acid-binding protein 4 (FABP4) is an important adipokine associated with inflammatory responses and metabolic regulation. Although a high-fat diet (HF) and/or HF-mediated obesity have been clearly linked to the progression of prostate cancer, with FABP4 potentially playing a critical role in …

jp (code pays fourni par la source)

Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old

K. Numakura, M. Kobayashi, Shingo Hatakeyama, Yuta Muto et autres

BRAF V600E mutation promoted excess of cortisol secretion in adrenal cortical adenoma

Kazuyuki Numakura, Yuta Muto, Yoshiki Sugiyama, M. Kobayashi et autres

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma

Kazuyuki Numakura, Ryoma Igarashi, Makoto Takahashi, Taketoshi Nara et autres

Objective Axitinib is an oral multi-target tyrosine kinase inhibitor used for the treatment of renal cell carcinoma (RCC). Because of the severe adverse events (AEs) associated with axitinib, patients often need dose reductions or discontinue its use, highlighting the need for effective …

jp (code pays fourni par la source)

BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report

Keisuke Okubo, Shintaro Narita, Atsushi Koizumi, Yoshiko Takahashi et autres

A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred …

jp (code pays fourni par la source)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto et autres

BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with …

jp (code pays fourni par la source)

Supplementary Material for: BRCA2 frameshift mutation in de novo small-cell neuroendocrine carcinoma of the prostate: a case report

Kenichi Okubo, Shintaro Narita, Ami Koizumi, Yusuke Takahashi et autres

A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred …

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab

Shuhei Takahashi, Shintaro Narita, Nobuhiro Fujiyama, Shingo Hatakeyama et autres

Human leukocyte antigen class I (HLA-I) genotypes are suggested to influence the cancer response to checkpoint blockade immunotherapy. This study assessed the impact of germline HLA genotypes on clinical outcomes in patients with chemoresistant advanced urothelial cancer (UC) treated with pembrolizumab. Zygosity, …

jp (code pays fourni par la source)

Factors Influencing Warm Ischemia Time in Robot-assisted Partial Nephrectomy Change Depending on the Surgeon’s Experience

Kazuyuki Numakura, Mizuki Kobayashi, Atsushi Koizumi, Soki Kashima et autres

Abstract INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical …

jp (code pays fourni par la source)

MP14-15 SEVERE IMMUNE-RELATED ADVERSE EVENTS IN NIVOLUMAB-TREATED PATIENTS WITH METASTATIC RCC ARE ASSOCIATED TO PDCD1 POLYMORPHISM

Mizuki Kobayashi, Kazuyuki Numakura, Shingo Hatakeyama, Yumina Muto et autres

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-15 SEVERE IMMUNE-RELATED ADVERSE EVENTS IN NIVOLUMAB-TREATED PATIENTS WITH METASTATIC RCC ARE ASSOCIATED TO PDCD1 POLYMORPHISM Mizuki Kobayashi, Kazuyuki Numakura, Shingo Hatakeyama, Yumina Muto, Yuya Sekine, Soki Kashima, Ryohei …

MP59-19 PERIOPERATIVE SERUM CYTOKINE LEVELS IN PATIENTS TREATED WITH ROBOT-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY

Atsushi Koizumi, Shintaro Narita, Soki Kashima, Ryohei Yamamoto et autres

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy V (MP59)1 Sep 2021MP59-19 PERIOPERATIVE SERUM CYTOKINE LEVELS IN PATIENTS TREATED WITH ROBOT-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY Atsushi Koizumi, Shintaro Narita, Soki Kashima, Ryohei Yamamoto, Taketoshi Nara, Mingguo Huang, Kazuyuki Numakura, Mitsuru Saito, Shigeru …

MP37-20 COMPARISON OF CLINICAL OUTCOME, SURGICAL INVASIVENESS, AND COSMETIC RESULTS OF CONVENTIONAL LAPAROSCOPIC SURGERY AND REDUCED-PORT SURGERY FOR LIVING DONOR NEPHRECTOMY

Mitsuru Saito, Shintaro Narita, Kazuyuki Numakura, Taketoshi Nara et autres

You have accessJournal of UrologyRenal Transplantation & Vascular Surgery I (MP37)1 Sep 2021MP37-20 COMPARISON OF CLINICAL OUTCOME, SURGICAL INVASIVENESS, AND COSMETIC RESULTS OF CONVENTIONAL LAPAROSCOPIC SURGERY AND REDUCED-PORT SURGERY FOR LIVING DONOR NEPHRECTOMY Mitsuru Saito, Shintaro Narita, Kazuyuki Numakura, Taketoshi Nara, Atsushi …